Russian drug spending set to reach US$4 billion by 2020

Home/Policies & Legislation | Posted 07/07/2010 post-comment0 Post your comment

Russia is planning to pump RUB 120 billion (US$4 billion) into its fledgling pharmaceutical sector this decade as part of a broader push to diversify the economy away from its traditional oil and gas industry.


"The development of Russian pharmaceuticals will not go through without help from the state” stated Industry Minister, Mr Viktor Khristenko.

Under its strategy for pharmaceutical sector development, Russia aims to increase local producers' share of total drug sales from its current 20% to 25% by 2012 and 50% by 2020.

The Russian government's plans include a range of incentives for locally-made products, such as faster registration and preferred status in the programme which supplies health care to those on low incomes.

According to the Russian Association of International Pharmaceutical Manufacturers, global drugmakers are ready to spend a combined US$1 billion on setting up local production in Russia. Multinationals which have announced plans to set up or extend manufacturing facilities in Russia, include AstraZeneca, GlaxoSmithKline, Novartis, Novo Nordisk, Pfizer, and Sanofi-aventis.

With growth in the Russian pharmaceutical market set to far outpace that for western nations and sales this year expected to grow by RUB 12% and US$ 18–20% this is looking like a very lucrative market.

By 2010, the Russian pharmaceutical market should be worth at least US$60 billion, and could rise as high as US$90 billion, according to Pharmexpert.


Reuters Article, Russia to spend $4 billion on pharma industry by 2020, 19 June 2010

Russian Association of International Pharmaceutical Manufacturers (AIPM) [homepage on the Internet]. Moscow, Russia: AIPM; c1994-2009 [cited 2010 June 22].

Pharmexpert, Main trends of Russia’s pharma market [page on the Internet]. Moscow, Russia: Pharmexpert; c1994-2009 [updated 2010 May 11; cited 2010 June 22].

comment icon Comments (0)
Post your comment
Related content
Strategic plans of ANVISA and COFEPRIS to advance health regulation
11 AA010165
Home/Policies & Legislation Posted 11/03/2024
Panama enacts new bill to guarantees the supply of medicines
53 MD002445
Home/Policies & Legislation Posted 29/02/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010